Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Achilles Therapeutics plc ACHL

Healthcare Biotechnology
Achilles Therapeutics plc is a United Kingdom-based clinical-stage immuno-oncology biopharmaceutical company. The Company is engaged in developing precision T cell therapies to treat multiple types of solid tumors. Its lead product is a precision tumor-derived T cell therapy targeting clonal cancer neoantigens. Its pipeline includes Chiron: Advanced Non-Small Cell Lung Cancer, Thetis: Melanoma (Monotherapy), Thetis: Melanoma (PD-1 Combination), and other indications. It is focused on advancing cancer therapies through its work in the field of tumor evolution. Its platform enables to identify mutations formed early in the development of a cancer that give rise to antigens that are expressed by all of a patient's cancer cells but are absent from healthy tissue. It refers to this class of solid tumor targets as clonal neoantigens. To identify clonal neoantigens in a patient, it has developed a bioinformatic platform called PELEUS.


NDAQ:ACHL - Post by User

Achilles Therapeutics plc
<< Previous
 Bullboard Posts
User Avatar Image
(259)
•••
Post by whytestockson Sep 19, 2024 10:02am
23 Views
Post# 36230819

Achilles Therapeutics Announces Strategic Update

Achilles Therapeutics Announces Strategic Update
Just In: $ACHL Achilles Therapeutics Announces Strategic Update&#x2013;Achilles to discontinue development of TIL-based cNeT therapy&#x2013; &#x2013;Cash position of $95.1 million as of June 30, 2024&#x2013; &#x2013;BofA Securities engaged to provide strategic financial advice&#x2013; LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeu...ACHL - Achilles Therapeutics Announces Strategic Update

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities